GLP-1 Drug Users Face Increased Surgical Risk, Study Warns

Patients taking glucagon-like peptide-1 (GLP-1) drugs, widely used for weight loss and diabetes management, may face an elevated risk of complications during surgery, according to new research presented at the Association of Anaesthetists of Great Britain and Ireland's annual meeting.

The study, which analyzed the medical records of over 47,000 adult patients undergoing elective or emergency procedures, found that those on GLP-1 medications were significantly more likely to experience regurgitation, including vomiting, during anesthesia. Of particular concern, a subset of these cases progressed to pulmonary aspiration, where stomach contents are inhaled into the lungs, a potentially life-threatening event.

Researchers observed that approximately 2.9% of patients in the study were taking GLP-1 drugs. Among this group, the incidence of regurgitation and/or pulmonary aspiration was about one in 71 patients. In contrast, for patients not taking these medications, the rate was approximately one in 802, an 11-fold difference.

GLP-1 medications mimic a natural gut hormone that slows digestion, leading to food remaining in the stomach for longer periods. Anesthesia, by relaxing the body and suppressing reflexes, can exacerbate this effect. When combined, there is a risk that stomach contents could be regurgitated and then aspirated into the lungs, bypassing the body's normal protective mechanisms.

While patients are typically instructed to fast before surgery to empty their stomachs, the prolonged gastric emptying associated with GLP-1s means that even after adhering to fasting guidelines, a significant amount of stomach contents may still be present. The study authors noted that current recommendations for patients to stop GLP-1s weeks before surgery might not be sufficient, suggesting that as many as 35 days may be needed for the drugs to be fully eliminated from the system.

The study acknowledged limitations, including the higher prevalence of obesity and diabetes among GLP-1 users, both of which are independent risk factors for pulmonary aspiration. This makes it challenging to isolate the exact contribution of the drugs themselves to the increased risk.

Despite these findings, the researchers emphasized that the overall probability of a GLP-1 user experiencing severe complications remains low. However, they highlighted the importance of patients informing their surgical and anesthesia teams about their use of these medications, as many patients obtain these drugs through non-traditional routes, such as telehealth services, which may lead to underreporting.

The findings underscore the need for further research to develop strategies that mitigate these surgical risks for patients taking GLP-1s. With projections indicating a substantial increase in GLP-1 drug usage in the coming years, addressing this potential perioperative complication is becoming increasingly critical.